vs
Burford Capital Ltd（BUR）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
Burford Capital Ltd的季度营收约是REGENXBIO Inc.的1.1倍（$33.4M vs $30.3M），Burford Capital Ltd净利率更高（-112.2% vs -221.3%，领先109.1%），Burford Capital Ltd自由现金流更多（$-29.3M vs $-52.8M）
伯福德资本成立于2009年，是一家面向法律市场的专业金融服务提供商，总部位于根西岛，业务覆盖全球。该公司为企业法务部门、律师事务所的诉讼、仲裁、资产追回等相关法律活动提供资金支持，同时也提供配套的法律金融咨询服务。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
BUR vs RGNX — 直观对比
营收规模更大
BUR
是对方的1.1倍
$30.3M
净利率更高
BUR
高出109.1%
-221.3%
自由现金流更多
BUR
多$23.5M
$-52.8M
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $33.4M | $30.3M |
| 净利润 | $-37.5M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | -37.9% | -190.0% |
| 净利率 | -112.2% | -221.3% |
| 营收同比 | — | 43.0% |
| 净利润同比 | — | -31.2% |
| 每股收益（稀释后） | $-0.16 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BURRGNX
| Q4 25 | $33.4M | $30.3M | ||
| Q3 25 | $69.8M | $29.7M | ||
| Q2 25 | $191.3M | $21.4M | ||
| Q1 25 | $118.9M | $89.0M | ||
| Q4 24 | — | $21.2M | ||
| Q3 24 | $159.7M | $24.2M | ||
| Q2 24 | $44.3M | $22.3M | ||
| Q1 24 | — | $15.6M |
净利润BURRGNX
| Q4 25 | $-37.5M | $-67.1M | ||
| Q3 25 | $-19.2M | $-61.9M | ||
| Q2 25 | $88.3M | $-70.9M | ||
| Q1 25 | $30.9M | $6.1M | ||
| Q4 24 | — | $-51.2M | ||
| Q3 24 | $53.7M | $-59.6M | ||
| Q2 24 | $-29.9M | $-53.0M | ||
| Q1 24 | — | $-63.3M |
毛利率BURRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率BURRGNX
| Q4 25 | -37.9% | -190.0% | ||
| Q3 25 | 35.5% | -176.3% | ||
| Q2 25 | 74.3% | -296.3% | ||
| Q1 25 | 65.4% | 13.6% | ||
| Q4 24 | — | -242.1% | ||
| Q3 24 | 76.1% | -256.6% | ||
| Q2 24 | 32.0% | -251.3% | ||
| Q1 24 | — | -408.8% |
净利率BURRGNX
| Q4 25 | -112.2% | -221.3% | ||
| Q3 25 | -27.4% | -208.3% | ||
| Q2 25 | 46.2% | -331.8% | ||
| Q1 25 | 26.0% | 6.8% | ||
| Q4 24 | — | -241.3% | ||
| Q3 24 | 33.7% | -246.3% | ||
| Q2 24 | -67.6% | -237.7% | ||
| Q1 24 | — | -405.4% |
每股收益（稀释后）BURRGNX
| Q4 25 | $-0.16 | $-1.30 | ||
| Q3 25 | $-0.09 | $-1.20 | ||
| Q2 25 | $0.39 | $-1.38 | ||
| Q1 25 | $0.14 | $0.12 | ||
| Q4 24 | — | $-0.99 | ||
| Q3 24 | $0.24 | $-1.17 | ||
| Q2 24 | $-0.14 | $-1.05 | ||
| Q1 24 | — | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $943.5M | $230.1M |
| 总债务越低越好 | $2.1B | — |
| 股东权益账面价值 | $2.4B | $102.7M |
| 总资产 | $6.6B | $453.0M |
| 负债/权益比越低杠杆越低 | 0.87× | — |
8季度趋势，按日历期对齐
现金及短期投资BURRGNX
| Q4 25 | $943.5M | $230.1M | ||
| Q3 25 | $677.7M | $274.2M | ||
| Q2 25 | $372.2M | $323.3M | ||
| Q1 25 | $486.6M | $267.9M | ||
| Q4 24 | — | $234.7M | ||
| Q3 24 | — | $255.5M | ||
| Q2 24 | — | $290.4M | ||
| Q1 24 | — | $338.7M |
总债务BURRGNX
| Q4 25 | $2.1B | — | ||
| Q3 25 | $2.1B | — | ||
| Q2 25 | $1.8B | — | ||
| Q1 25 | $1.8B | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益BURRGNX
| Q4 25 | $2.4B | $102.7M | ||
| Q3 25 | $2.5B | $161.5M | ||
| Q2 25 | $2.5B | $213.7M | ||
| Q1 25 | $2.4B | $274.2M | ||
| Q4 24 | — | $259.7M | ||
| Q3 24 | $3.2B | $301.4M | ||
| Q2 24 | $3.1B | $348.3M | ||
| Q1 24 | — | $390.7M |
总资产BURRGNX
| Q4 25 | $6.6B | $453.0M | ||
| Q3 25 | $6.7B | $525.2M | ||
| Q2 25 | $6.3B | $581.0M | ||
| Q1 25 | $6.2B | $490.9M | ||
| Q4 24 | — | $466.0M | ||
| Q3 24 | — | $519.1M | ||
| Q2 24 | — | $569.4M | ||
| Q1 24 | — | $629.2M |
负债/权益比BURRGNX
| Q4 25 | 0.87× | — | ||
| Q3 25 | 0.86× | — | ||
| Q2 25 | 0.71× | — | ||
| Q1 25 | 0.72× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-29.0M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $-29.3M | $-52.8M |
| 自由现金流率自由现金流/营收 | -87.7% | -174.0% |
| 资本支出强度资本支出/营收 | 0.8% | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $21.4M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流BURRGNX
| Q4 25 | $-29.0M | $-52.3M | ||
| Q3 25 | $-20.1M | $-56.0M | ||
| Q2 25 | $-84.2M | $-49.3M | ||
| Q1 25 | $155.2M | $33.6M | ||
| Q4 24 | — | $-31.6M | ||
| Q3 24 | $-97.4M | $-40.5M | ||
| Q2 24 | $53.0M | $-45.5M | ||
| Q1 24 | — | $-55.5M |
自由现金流BURRGNX
| Q4 25 | $-29.3M | $-52.8M | ||
| Q3 25 | $-20.1M | $-56.5M | ||
| Q2 25 | $-84.3M | $-49.7M | ||
| Q1 25 | $155.1M | $32.6M | ||
| Q4 24 | — | $-32.7M | ||
| Q3 24 | $-97.4M | $-40.9M | ||
| Q2 24 | $52.9M | $-46.0M | ||
| Q1 24 | — | $-56.0M |
自由现金流率BURRGNX
| Q4 25 | -87.7% | -174.0% | ||
| Q3 25 | -28.8% | -189.9% | ||
| Q2 25 | -44.1% | -232.8% | ||
| Q1 25 | 130.5% | 36.6% | ||
| Q4 24 | — | -154.2% | ||
| Q3 24 | -61.0% | -168.9% | ||
| Q2 24 | 119.5% | -206.2% | ||
| Q1 24 | — | -358.5% |
资本支出强度BURRGNX
| Q4 25 | 0.8% | 1.7% | ||
| Q3 25 | 0.1% | 1.7% | ||
| Q2 25 | 0.1% | 1.8% | ||
| Q1 25 | 0.0% | 1.2% | ||
| Q4 24 | — | 5.1% | ||
| Q3 24 | 0.0% | 1.3% | ||
| Q2 24 | 0.1% | 2.1% | ||
| Q1 24 | — | 3.6% |
现金转化率BURRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -0.95× | — | ||
| Q1 25 | 5.02× | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | -1.81× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BUR
| Principal Finance Segment | $29.1M | 87% |
| Other | $3.5M | 10% |
| Management Fee Income | $878.0K | 3% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
